Octreotide vs Lanreotide
How they differ
- FDA status, the same for both (FDA-approved). Octreotide: FDA-approved as Sandostatin and other octreotide products.1,2,3,4,5 Lanreotide: FDA-approved as Somatuline Depot and other lanreotide products.6,7,8,9
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | Octreotide | Lanreotide |
|---|---|---|
| What it is | A somatostatin analogue. The label states that it acts like natural somatostatin and is an even more potent inhibitor of growth hormone, glucagon and insulin.1 | A somatostatin analogue. The label describes lanreotide as an octapeptide, eight amino acids long, that is thought to act like natural somatostatin.6 |
| FDA status | FDA-approved FDA-approved as Sandostatin and other octreotide products1,2,3,4,5 FDA-approved. Drugs@FDA lists Sandostatin with an original approval date of October 21, 1988, and later octreotide products including Sandostatin LAR, Mycapssa and Bynfezia. The cited label has no boxed warning.1,2,3,4,5 | FDA-approved FDA-approved as Somatuline Depot and other lanreotide products6,7,8,9 FDA-approved. Drugs@FDA lists Somatuline Depot with an original approval date of August 30, 2007, and later lanreotide applications. The cited label has no boxed warning.6,7,8,9 |
| HHS compounding policy, October 30, 2026 | Not among the six peptides the policy lists.10 | Not among the six peptides the policy lists.10 |
| FDA compounding safety-risk page | Not addressed in this profile’s sources. | Not addressed in this profile’s sources. |
| Kinds of studies cited | Smaller controlled human trials
| Smaller controlled human trials
|
| Records collected | 57 ClinicalTrials.gov records and 64 PubMed records collected | 13 ClinicalTrials.gov records and 49 PubMed records collected |
| Area of study | ||
| Latest dated events |
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1Octreotide acetate injection, solution · SPL version 2 · published 2026-02-02 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 2Drugs@FDA application NDA019667 · original submission status AP · 1988-10-21 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 3Drugs@FDA application NDA021008 · original submission status AP · 1998-11-25 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 4Drugs@FDA application NDA208232 · original submission status AP · 2020-06-26 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 5Drugs@FDA application NDA213224 · original submission status AP · 2024-09-27 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 6Lanreotide acetate injection · SPL version 3 · published 2025-06-02 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 7Drugs@FDA application NDA022074 · original submission status AP · 2007-08-30 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 8Drugs@FDA application NDA215395 · original submission status AP · 2021-12-17 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 9Drugs@FDA application ANDA217193 · original submission status AP · 2024-05-21 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 10HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 11Sandostatin LAR Depot (octreotide acetate) prescribing information, NDA 021008 supplement S-049, revised July 2024 ↗
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
- 12Mycapssa (octreotide) prescribing information, NDA 208232 supplement S-006, revised July 2024 ↗
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
- 13Short term treatment of acromegaly with the somatostatin analog octreotide: the first double-blind randomized placebo-controlled study on its effects (1990) · PMID 2229278 ↗
The Journal of Clinical Endocrinology & Metabolism · Official source · Source checked November 14, 2026
- 14Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial (MPOWERED, 2022) · PMID 34953531 ↗
The Lancet Diabetes & Endocrinology · Official source · Source checked November 14, 2026